Cohort Analysis of Patients With Localized, High-Risk, Extremity Soft Tissue Sarcoma Treated at Two Cancer Centers: Chemotherapy-Associated Outcomes

Janice N. Cormier, Xuelin Huang, Yan Xing, Peter F. Thall, Xuemei Wang, Robert S. Benjamin, Raphael E. Pollock, Cristina R. Antonescu, Robert G. Maki, Murray F. Brennan, and Peter W.T. Pisters

ABSTRACT

Purpose
Patients with American Joint Committee on Cancer stage III soft tissue sarcoma (STS) have high risks of distant recurrence and death. The role of chemotherapy for these patients remains controversial despite several randomized trials and a meta-analysis.

Methods
We reviewed the treatments and outcomes of 674 consecutive adult patients presenting with primary stage III extremity STS between 1984 and 1999. Pre- or postoperative doxorubicin-based chemotherapy was used in a nonrandomized fashion in approximately half of this high-risk population. The objective of this review was to evaluate the impact of chemotherapy while accounting for known prognostic variables.

Results
Among 674 patients, 338 (50%) were treated with local therapy only, and 336 (50%) were treated with local therapy plus chemotherapy. The median follow-up for survivors was 6.1 years. Five-year local and distant recurrence-free interval probabilities were 83% and 56%, respectively, for the two groups combined. The 5-year disease-specific survival (DSS) rate was 61%. Cox regression analyses showed a time-varying effect associated with chemotherapy. During the first year, the hazard ratio associated with DSS for patients treated with chemotherapy versus no chemotherapy was 0.37 (95% CI, 0.20 to 0.69; \( P = .002 \)). Thereafter, this hazard ratio was 1.36 (95% CI, 1.02 to 1.81; \( P = .04 \)).

Conclusion
It seems that the clinical benefits associated with doxorubicin-based chemotherapy in patients with high-risk extremity STS are not sustained beyond 1 year. These results suggest that caution should be used in the interpretation of randomized clinical trials of adjuvant chemotherapy that seem to demonstrate clinical benefits with relatively short-term follow-up.

J Clin Oncol 22:4567-4574. © 2004 by American Society of Clinical Oncology

INTRODUCTION

Soft tissue sarcomas (STS) can occur anywhere in the body; the majority (50%) of primary tumors originate in an extremity. Patients with large (> 5 cm), deep, high-grade, extremity STS (American Joint Committee on Cancer [AJCC] stage III) are at significant risk for distant recurrence and subsequent sarcoma-related death. As a consequence, patients with stage III disease are often considered for pre- or postoperative anthracycline-based chemotherapy.

The Sarcoma Meta-Analysis Collaboration (SMAC) performed a meta-analysis of all randomized trials comparing adjuvant chemotherapy to no adjuvant therapy for STS arising from extremity, trunk, head and neck, or visceral sites. In this meta-analysis of 14 published trials, doxorubicin-based...
adjuvant chemotherapy was associated with decreased local and distant recurrence rates, and an increased recurrence-free survival rate, but not an increased overall survival (OS) rate. However, in a subset analysis of the 886 patients with extremity STS, adjuvant chemotherapy was associated with a possible OS benefit, estimated to be 7%. A later randomized prospective trial of 104 patients with high-risk primary and locally recurrent extremity and limb girdle STS showed a significant difference in OS (75 v 46 months; P = .03) for those treated with surgery plus chemotherapy versus those treated with definitive surgical resection alone. Two additional randomized trials (59 and 88 patients, respectively) in patients with primary and locally recurrent STS at heterogeneous anatomic sites also showed improvements in the 5-year OS rate associated with adjuvant chemotherapy, although the differences were not statistically significant. The interpretation of this complex literature is difficult.

As a result of the inconclusive body of evidence, there is still considerable variation in regional and international treatment recommendations for patients with high-risk localized STS. We retrospectively analyzed our combined institutional experience to evaluate the effects of adjuvant chemotherapy in a homogeneous population of patients with high-risk (AJCC stage III) extremity STS.

METHODS

Patients

The study population was derived from 8,257 consecutive patients with a diagnosis of STS presenting to Memorial Sloan-Kettering Cancer Center (MSKCC) and the University of Texas M.D. Anderson Cancer Center (MDACC) from January 1, 1984, to June 29, 1999. From this group, 2,135 patients were determined to have nonmetastatic disease arising from an extremity. Patients with stage I and II tumors and locally recurrent disease, as well as patients not treated with definitive surgical resection (ie, patients treated with palliative intent), were excluded. The resulting cohort consisted of 674 patients presenting with primary, high-risk (AJCC [6th edition] stage III) extremity STS treated during this time period. Three hundred eighty-six patients (57%) were included for the first year effects, whereas effects thereafter were based on the subgroup of 591 patients who survived at least 1 year and thereafter were analyzed separately. In these analyses, all patients were included for the first year and thereafter were analyzed separately. In these analyses, all patients were included for the first year effects, whereas effects thereafter were based on the subgroup of 591 patients who survived the first year. The comparisons for the subgroup of patients who survived at least 1 year should be interpreted with caution because deaths occurring during the first year may have rendered the treatment groups less comparable after 1 year. All computations were carried out using SAS statistical software version 8.02 (SAS Institute, Cary, NC) on a Compaq EVO 500 computer. A P value of less than .05 was regarded as statistically significant.
RESULTS

The median follow-up time for survivors was 6.1 years. Eighty-eight percent of patients underwent limb-sparing surgical resection, and 75% of patients had microscopically negative (R0) surgical margins. Patients with unknown margin status were considered to have microscopically positive surgical margins (R1) in subsequent analyses. Three hundred thirty-six patients (50%) received chemotherapy; 214 (64%) of these received preoperative chemotherapy, whereas 122 (35%) patients were treated with postoperative chemotherapy. Of the 332 patients for whom there is information on the chemotherapy regimen used, 88% received doxorubicin either alone or in combination with other drugs (dacarbazine with or without cyclophosphamide, or ifosfamide with or without dacarbazine and mesna). The distributions of clinicopathologic factors within the subgroups of patients who did and did not receive chemotherapy are listed in Table 1. The use of chemotherapy differed among age cohorts: 62%, 55%, and 38% of patients younger than 40 years, 40 to 60 years, and over 60 years, respectively, were treated with chemotherapy. Reflecting the fact that younger patients were more likely to receive chemotherapy, the median age of chemotherapy patients was 51 v 60 years for patients not treated with chemotherapy (P < .0001). Patients treated at MDACC were more likely to receive chemotherapy than those treated at MSKCC (57% v 43%; P < .0001). Table 2 lists the hazard ratios (HRs) from Cox regression analyses of clinicopathologic factors for all of the outcomes. Additional covariates included in the Cox model are treatment site, histopathologic classification, and local treatment with radiation (classified as preoperative, postoperative, or brachytherapy).

Pretreatment Prognostic Factors

Local recurrence end points. One hundred eleven patients (16%) had one or more local recurrences. The median time to first local recurrence among these 111 patients was 1.42 years, whereas the overall median time to first local recurrence has not been reached. The KM

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>All (N = 674)</th>
<th>Chemotherapy (n = 336)</th>
<th>No Chemotherapy (n = 338)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median age, years*</td>
<td>55.3</td>
<td>50.7</td>
<td>60.3</td>
</tr>
<tr>
<td>Median tumor size, cm</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt; 5 to &lt; 10</td>
<td>10</td>
<td>10</td>
<td>9.75</td>
</tr>
<tr>
<td>10 to &lt; 15</td>
<td>312</td>
<td>143</td>
<td>42</td>
</tr>
<tr>
<td>≥ 15</td>
<td>212</td>
<td>113</td>
<td>34</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>379</td>
<td>189</td>
<td>56</td>
</tr>
<tr>
<td>Female</td>
<td>295</td>
<td>147</td>
<td>44</td>
</tr>
<tr>
<td>Anatomic site</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upper extremity</td>
<td>105</td>
<td>48</td>
<td>14</td>
</tr>
<tr>
<td>Lower extremity</td>
<td>569</td>
<td>298</td>
<td>86</td>
</tr>
<tr>
<td>Distal extremity</td>
<td>186</td>
<td>89</td>
<td>26</td>
</tr>
<tr>
<td>Proximal extremity</td>
<td>488</td>
<td>247</td>
<td>74</td>
</tr>
<tr>
<td>Histopathologic subtype</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malignant fibrous histiocytoma</td>
<td>250</td>
<td>129</td>
<td>38</td>
</tr>
<tr>
<td>Liposarcoma</td>
<td>116</td>
<td>47</td>
<td>14</td>
</tr>
<tr>
<td>Synovial sarcoma</td>
<td>89</td>
<td>47</td>
<td>14</td>
</tr>
<tr>
<td>Unclassified sarcoma</td>
<td>53</td>
<td>29</td>
<td>9</td>
</tr>
<tr>
<td>Leiomyosarcoma</td>
<td>42</td>
<td>15</td>
<td>4</td>
</tr>
<tr>
<td>Other</td>
<td>124</td>
<td>69</td>
<td>21</td>
</tr>
<tr>
<td>Microscopic resection margin status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>R0</td>
<td>503</td>
<td>254</td>
<td>76</td>
</tr>
<tr>
<td>R1 or unknown</td>
<td>171</td>
<td>82</td>
<td>24</td>
</tr>
<tr>
<td>Location of treatment*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MSKCC</td>
<td>396</td>
<td>146</td>
<td>43</td>
</tr>
<tr>
<td>MDACC</td>
<td>288</td>
<td>190</td>
<td>57</td>
</tr>
</tbody>
</table>

Abbreviations: AJCC, American Joint Committee on Cancer; R0, microscopically negative surgical margins; R1, microscopically positive surgical margins; MSKCC, Memorial Sloan-Kettering Cancer Center; MDACC, University of Texas M.D. Anderson Cancer Center.

*Significant difference between treatment groups.
estimates of local RFI at 5 and 10 years were 83% (95% CI, 79% to 86%) and 77% (95% CI, 73% to 82%), respectively. The KM estimates of local DFS at 5 and 10 years were 55% (95% CI, 51% to 59%) and 44% (95% CI, 40% to 49%), respectively. In the multivariate analysis, tumor size more than 15 cm was an independent adverse prognostic factor (HR, 1.51; 95% CI, 1.12 to 2.04; Table 2).

Distant recurrence end points. Three hundred five patients (45%) had distant recurrences. The median time to first distant recurrence among these 305 patients was 1.07 years, whereas the overall median time to distant recurrence was 8.87 years. Two hundred sixty-one patients (39%) had distant metastases as their first site of recurrence. The KM estimates of distant RFI at 5 and 10 years were 61% (95% CI, 57% to 65%) and 50% (95% CI, 46% to 55%), respectively. The distant DFS rates at 5 and 10 years were 55% (95% CI, 51% to 59%) and 44% (95% CI, 40% to 49%), respectively. In the multivariate analysis, tumor size more than 15 cm was an independent adverse prognostic factor (HR, 1.51; 95% CI, 1.12 to 2.04; Table 2).

Overall DFS. Three hundred sixty-four patients (54%) died or had recurrent disease. The median time to death or recurrence among these 364 patients was 1.06 years, whereas the overall median time to death or recurrence was 3.79 years. The overall DFS rates were 48% (95% CI, 44% to 52%) and 41% (95% CI, 37% to 46%) at 5 and 10 years, respectively. Tumor size more than 15 cm (HR, 1.62; 95% CI, 1.22 to 2.17; P = .001) and female sex (HR, 0.79; 95% CI, 0.64 to 0.99; P = .04) were the only independent prognostic factors for overall DFS (Table 2).

DSS. Two hundred eighty-seven patients (43%) died as a result of STS, five (0.7%) had treatment-related deaths (surgery-related death, two patients [0.3%]; chemotherapy-related death, three patients [0.4%]), and 74 (11%) died as a result of other causes. The median time to disease-specific death among the 287 patients was 2 years, whereas the overall median time to disease-specific death was 11 years. The DSS rates at 5 and 10 years were 61% (95% CI, 57% to 65%) and 50% (95% CI, 46% to 55%), respectively. Tumor size more than 15 cm (HR, 1.56; 95% CI, 1.14 to 2.13; P = .006) and female sex (HR, 0.77; 95% CI, 0.60 to 0.98; P = .03) were the only independent prognostic factors for DSS (Table 2).

Effects of Chemotherapy

Of the 336 patients treated with chemotherapy, 147 (44%) were alive at last follow-up, 151 (45%) died as a result of disease, 35 (10%) died as a result of other causes, and three (0.9%) died as a result of treatment-related complications. The 338 patients not treated with chemotherapy, 166 (49%) were alive, 131 (39%) died as a result of disease, 39 (12%) died as a result of other causes, and two (0.6%) died as a result of treatment-related complications. A striking feature of the KM survival probability curves for patients treated with chemotherapy and for those who did not receive chemotherapy was that these curves crossed. This pattern persisted for local, distant, and overall DFS and DSS. This violates the
proportional hazards assumption underlying the Cox model, and it indicates that effects associated with chemotherapy may vary over time. The estimated times, in years, at which the chemotherapy and no-chemotherapy hazard function curves crossed are 1.19 (95% CI, 0.80 to 1.33) for DSS, 0.72 (95% CI, 0.43 to 0.93) for DFS, 0.81 (95% CI, 0.63 to 1.22) for local DFS, and 0.76 (95% CI, 0.40 to 1.07) for distant DFS. Figure 1 demonstrates this for DSS in terms of the hazard (instantaneous rate) of death, which initially is low in patients treated with chemotherapy but exhibits a sharp increase during the first 2 years. Patients not treated with chemotherapy had an initially higher hazard that steadily declined during 5 years. This indicates that among patients who survived at least 1 year, those who received chemotherapy had a higher risk of death thereafter compared with patients who did not receive chemotherapy. Because the hazard functions associated with chemotherapy and no-chemotherapy crossed at times that varied from 0.4 to 1.3 years, depending on the outcome examined, 1 year was chosen as the cut point for describing the time-varying effects of chemotherapy in subsequent analyses. KM survival plots for all end points are presented in Figure 2. Survival plots for chemotherapy and no chemotherapy adjusted for other prognostic factors and patient characteristics also crossed. They are not presented because they were similar to KM estimates.

Local recurrence end points. KM estimates of local RFI for patients treated with chemotherapy versus no chemotherapy were 94% (95% CI, 92% to 97%) vs 92% (95% CI, 89% to 95%) at 1 year and 83% (95% CI, 78% to 87%) vs 83% (95% CI 78% to 88%) at 5 years, respectively (Fig 2A). Multivariate analysis indicated that patients treated with local therapy plus chemotherapy experienced no significant difference in local RFI in the first year or beyond the first year compared with those treated with local therapy alone (Fig 3).

KM estimates of local DFS for patients treated with chemotherapy versus no chemotherapy were 81% (95% CI, 77% to 85%) vs 76% (95% CI, 71% to 80%) at 1 year and 55% (95% CI, 50% to 61%) vs 57% (95% CI, 51% to 63%) at 5 years, respectively (Fig 2C). Multivariate analysis indicated that patients treated with local therapy plus chemotherapy experienced a lower hazard for distant metastasis than patients treated with local therapy alone in the first year (HR, 0.67; 95% CI, 0.46 to 0.96; P = .03). Beyond the first year, patients treated with chemotherapy fared worse with respect to distant RFI (HR, 1.54; 95% CI, 1.09 to 2.17; P = .01; Fig 3).

KM estimates of distant DFS for patients treated with chemotherapy versus no chemotherapy were 81% (95% CI, 77% to 85%) vs 75% (95% CI, 70% to 79%) at 1 year and 52% (95% CI, 47% to 58%) vs 53% (95% CI, 48% to 59%) at 5 years, respectively (Fig 2D). Multivariate analysis indicated that patients treated with local therapy plus chemotherapy fared better with respect to DFS than patients treated with local therapy alone in the first year (HR, 0.64; 95% CI, 0.45 to 0.91; P = .01) but fared worse beyond the first year (HR, 1.46; 95% CI, 1.08 to 1.96; P = .01; Fig 3).

Overall DFS. KM estimates for overall DFS for patients treated with chemotherapy versus no chemotherapy were 77% (95% CI, 72% to 82%) vs 71% (95% CI, 66% to 76%) at 1 year and 47% (95% CI, 42% to 53%) vs 49% (95% CI, 44% to 55%) at 5 years, respectively (Fig 2E). Multivariate analysis indicated that patients treated with local therapy plus chemotherapy fared better with respect to overall DFS than patients treated with local therapy alone in the first year (HR, 0.67; 95% CI, 0.48 to 0.93; P = .02) but fared worse, although not statistically significantly so, beyond the first year (HR, 1.33; 95% CI, 0.97 to 1.81; P = .08; Fig 3).

DSS. KM estimates of DSS for patients treated with chemotherapy versus no chemotherapy were 95% (95% CI, 93% to 98%) vs 87% (95% CI, 84% to 91%) at 1 year and 60% (95% CI, 55% to 65%) vs 62% (95% CI, 56% to 67%) at 5 years, respectively (Fig 2F). Among all end points evaluated, DSS exhibited the largest change in hazard for chemotherapy versus no chemotherapy, with an HR for disease-specific death of 0.37 (95% CI, 0.20 to 0.69; P = .002) in the first year and 1.36 (95% CI, 1.02 to 1.81; P = .04) after the first year (Fig 3).
Fig 2. Kaplan-Meier curves of local recurrence-free interval (A), local disease-free survival (B), distant recurrence-free interval (C), distant disease-free survival (D), overall disease-free survival (E), and disease-specific survival (F) for chemotherapy versus no chemotherapy.
In our covariate-adjusted analysis of 674 patients with stage III extremity STS, the observed effects of chemotherapy varied over time. The instantaneous hazard function curves for patients treated with chemotherapy compared with patients treated without chemotherapy crossed at approximately 1 year after the initiation of treatment. Given that the proportional hazards assumption is violated, the effects of being treated with chemotherapy cannot be characterized by a single parameter. Consequently, we analyzed these effects over two distinct time periods: the interval up to 1 year and the interval beyond 1 year. Total benefits associated with chemotherapy in the first year were estimated to be 7%, 6%, 6%, and 8% for local, distant, and overall DFS and DSS, respectively. However, at 5 years, the use of chemotherapy was associated with higher rates of disease recurrence and lower DFS and DSS, with cumulative 2%, 1%, 2%, and 2% decrements in local, distant, and overall DFS and DSS, respectively. Thus, chemotherapy seemed to result in no long-term benefits.

This study included a homogeneous population of high-risk patients with STS traditionally considered likely to benefit from chemotherapy. The chemotherapy and no-chemotherapy subgroups were balanced with respect to known prognostic factors, except that younger patients were more likely to have received chemotherapy ($P < .001$). Given that our model adjusted for age as well as all other known prognostic factors, its estimates of the effects of chemotherapy were unlikely to have been confounded by the observed difference in the age distribution. Nevertheless, if the effects of chemotherapy were confounded by age, this might explain the early benefits seen with chemotherapy but not the subsequent adverse effects.

Although the patient population in this study was homogeneous and the analyses were adjusted for known prognostic factors, interpretation of these data must take into account that patients were not randomly assigned between chemotherapy and no chemotherapy. Although the Cox model can adjust for known clinicopathologic and treatment factors, we cannot exclude the possibility that the time-varying effects of chemotherapy arose as a consequence of an imbalance in unknown confounding factors. For example, the use of potentially less efficacious chemotherapy regimens (doses and agents) in one group might account for some of the effects observed. These and additional subset analyses will be addressed in subsequent reports. The retrospective nature of our analysis also does not allow us to draw conclusions about the mechanism(s) underlying the time-varying effects of chemotherapy. There may be biologic reasons for the eventual unfavorable effects associated with chemotherapy.

To our knowledge, the current report of 674 patients is the largest observational study evaluating the effects of chemotherapy in patients with high-risk extremity STS. When considering sample size and number of observed events, the current report may be compared and contrasted with the SMAC meta-analysis. Several points merit comment. First, the meta-analysis was based on pooled individual patient data from randomized trials in heterogeneous patient populations with STS, whereas this report is a retrospective
analysis comparing nonrandomized treatments in a homogeneous population. Second, the meta-analysis included patients with primary (89%) or recurrent (11%) STS arising in extremity (58%) and nonextremity (42%) anatomic sites, whereas this report was restricted to patients with primary extremity tumors. Third, the meta-analysis combined data from a number of treatment centers and was performed with significant missing covariate data. For example, 28% and 37% of patient cases were missing tumor grade and size, respectively. In contrast, this analysis was based on a data set from two institutions with no missing covariate data. Fourth, the SMAC meta-analysis included patients with significant tumor heterogeneity. For example, 17% of patients had uterine sarcomas and 5% of patients had low-grade sarcomas. In addition, in the subset of patients with extremity STS in the SMAC meta-analysis, 40% of patient cases had tumor size less than 5 cm—a subset of patients with generally more favorable outcomes. In contrast, our report was based on a homogeneous patient population; all patients had large (> 5 cm), high-grade sarcomas located beneath the investing fascia of the extremity. Given the general limitations of meta-analysis, the specific limitations of the SMAC meta-analysis, and the conflicting body of relatively small randomized trials, there is no consensus on the role of chemotherapy in patients with localized high-risk STS. In this context, retrospective reports such as ours may provide important observations that add to the existing body of literature.

In summary, this retrospective analysis of patients with high-risk extremity STS treated at two cancer centers over a 16-year period suggests that the use of chemotherapy is associated with time-varying clinical effects. During the first year, there seem to be improvements in clinical outcomes; thereafter, the effect seems to be reversed, with the use of chemotherapy associated with lower DFS and DSS. These results suggest that caution should be used in interpreting randomized clinical trials of adjuvant chemotherapy that seem to demonstrate clinical benefits with relatively short-term follow-up. Given the ongoing controversy regarding the role of chemotherapy for high-risk localized STS, we recommend that patients with stage III extremity STS who are considering doxorubicin-based chemotherapy be informed that the initial clinical benefits of chemotherapy may not be sustained over time.

Acknowledgment
We thank Melissa Burkett for her editorial assistance.

Authors’ Disclosures of Potential Conflicts of Interest
The authors indicated no potential conflicts of interest.

REFERENCES